Brought to you by 
Roche licenses IPF candidate to Ark Biosciences
09 Mar 2022
Executive Summary
Roche’s Genentech Inc. licensed Ark Biosciences Inc. exclusive worldwide development and commercialization rights to its Phase I idiopathic pulmonary fibrosis (IPF) program AK3280 (GDC3280) plus related compounds.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche licenses IPF candidate to Ark Biosciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice